The half-life of the two most abundant proteins in blood, immunoglobulin G (IgG) and serum albumin, is extraordinary (¿19-23 days) compared to other circulating proteins. This phenomenon secures a broad biodistribution throughout the body of both molecules. The long half-life has made IgG the natural choice for engineering of antibody based therapeutics, while albumin is used as a fusion partner for or carrier of drugs. Remarkably, the half-life of these unrelated proteins has been shown prolonged by a receptor recycling pathway mediated by a common cell bound receptor named the neonatal Fc receptor (FcRn). This review summarizes our current understanding of FcRn function and discusses its relevance for development of new IgG and albumin based therapeutics and diagnostics.
Introduction
Serum albumin and immunoglobulin G (IgG) are the two most abundant circulating proteins in the bloodstream, amounting up to an incredible 80-90% of total plasma protein. Albumin is a multi-binding transporter produced by the liver with a broad binding capacity towards a plethora of different insoluble and hydrophobic endogenous and exogenous ligands, such as ions, fatty acids, amino acids as well as a range of biomedical drugs. 1) Albumin is also an important antioxidant and possesses enzymatic properties and is central in maintaining osmotic blood pressure. 1, 2) The human serum albumin (HSA) three-dimensional architecture is well characterized by X-ray structure analysis that reveals three structurally homologous domains (DI, DII and DIII), each containing two sub-domains (A and B) connected via flexible loops. 3, 4) Each domain possesses binding activity and a total of seven binding sites for fatty acids has been described. 5, 6) The crystal structure of HSA is shown in Figure 1A .
The unrelated IgG is the predominant antibody (Ab) isotype present in blood and extravascular space and acts in the humoral immune system by linking recognition of foreign antigens to several effector arms. IgG is a symmetric protein that consists of two light chains and two heavy chains that forms two main parts, the Fab (fragment of antigen binding) and the Fc (fragment crystallizable). Each antibody has two Fabs and one Fc. The Fab arms carry binding specificity for foreign substances, whereas the unique signature of the constant Fc region of each antibody class is specific for distinct Fc receptors on immune cells that mediate downstream elimination of the Fab bound antigen. Five classes of Abs are present in humans: IgA, IgD, IgE, IgG and IgM. They are produced by B and plasma cells using a highly sophisticated gene rearrangement mechanism to produce a manifold set of Fab specificities. Combined with class switching, this generates antibody classes with broad specificity, while the Fc signature secures specific tissue localization and effector cell recognition. The crystal structure of human IgG1 is shown in Figure 1B .
Despite their unrelated biological roles, IgG and albumin share a half-life of 19-22 days in humans compared with a few days for other circulating proteins. [7] [8] [9] Surprisingly, a common molecular mechanism explains the extended half-life of both, as it has become apparent that a single broadly expressed receptor named the neonatal Fc receptor, FcRn, is the key homeostatic regulator. 10, 11) This review reports the current molecular and cellular Fig. 1 . The crystal structures of HSA and human IgG1 (A) The crystal structure of HSA with three sub-domains highlighted, DI and DII in gray and DIII in green. Unpaired C34 in DI is highlighted as a red spherical ball. (B) The crystal structure of human IgG1. The two identical heavy chains, consisting of Fab arms genetically bound to the constant Fc via the hinge, are highlighted in green and gray, while the light chains are highlighted in blue. The biantennary glycan attached to N297 localized within C H 2 is highlighted in red. The figures were designed using PyMOL (DeLano Scientific) with the crystallographic data of HSA and human IgG1. 159, 160) 319 FcRn Functions understanding of FcRn biology and discusses how this knowledge sheds new light on the development of IgG and albumin based diagnostics and therapeutics.
FcRn from a Historical Perspective F. W. Rogers Brambell (1901 Brambell ( -1970 ) is the father of FcRn. He reported that IgG is actively and prenatally transported from mother to fetus in rabbits via the yolk sac. 12, 13) In parallel, maternal IgG in rodents has been shown absorbed from the gut of neonatal rats up to day 18-21 post birth after which the transport quickly ceases. 14, 15) In vitro intestinal cell assay 16) has shown the transport to be highly selective for the IgG isotype and fundamentally dependent on its constant Fc part. Based on these observations, Brambell proposed that a single cell bound receptor with specificity for the Fc part of the IgG molecule transports IgG transcellularly. 12) Studies by Fahey and Robinson elegantly demonstrate that IgG is eliminated from the systemic circulation in a concentration-dependent manner, since the presence of IgG is inversely related to its blood concentration. 17) Notably, injection of high doses of endogenous IgG in mice dramatically accelerated the clearance of IgG, while excess amounts of IgA, IgM or serum albumin had no impact on IgG half-life. In line with the findings on transepithelial transport, half-life was also fundamentally dependent on the IgG Fc part.
Brambell recognized the resemblance to his own studies and proposed a common hypothesis encompassing both maternofetal transport and systemic half-life regulation. 12, 18) The hypothesis describes a receptor that resides within cells with binding specificity for the Fc part of IgG. Subsequently, the receptor should salvage bound IgG from intracellular degradation by transcellularly transport or by recycling back to the cell surface for release into the circulation. Both pathways are saturable since their transport efficiencies are totally dependent on and limited by the level of expression of the receptor.
In the late 1980s, identity of the proposed receptor was revealed when it was cloned from the intestinal epithelium of neonatal rodents. 19) The breakthrough inspired its name, the neonatal Fc receptor, abrogated as FcRn. Subsequently, studies on intestinal epithelium at the time of weaning, showed that FcRn was downregulated post birth, a finding that nicely correlates with decreased absorption of maternal IgG. 20, 21) In contrast, rodent FcRn was expressed throughout adult life in the vascular endothelium, which explains the homeostatic half-life regulation of IgG, as extensively reviewed.
11)
Furthermore, the expression of FcRn in humans has been found remarkably wide, and detects levels of expression in several organs and tissues, including the kidneys, [22] [23] [24] the liver [25] [26] [27] and placenta. 28, 29) The functional role in each organ or tissue has only recently begun to be uncovered as discussed below.
In contrast to the well characterized IgG-FcRn relationship, a molecular explanation for the extraordinarily long half-life of serum albumin has been a matter of debate for decades, until Anderson and coworkers reported that albumin binds to FcRn. 10) The interaction was discovered by chance when bovine albumin was eluted together with a recombinant soluble form of human FcRn from an IgG affinity column. The observation revitalized a hypothesis put forward by Shultze and Heremans during the 1960s that a single receptor is responsible for the half-life regulation of albumin, 30) similar to that proposed by Brambell for IgG. The hypothesis was finally verified when the half-life of albumin turned out to be reduced in FcRn-deficient mice.
10)

Structural Architecture of FcRn
The cloning of rat FcRn identified a receptor related to major histocompatibility (MHC) class I molecules with sequence similarity of approximately 20-40%, greatest in the a3-domain. 19) Both MHC class I and FcRn each consist of a heavy chain with a large extracellular part that associates with the common b2-microglobulin subunit followed by a transmembrane segment and a short cytoplasmic tail.
The extracellular portion of FcRn has been produced as a soluble truncated heterodimeric molecule with retained IgG binding properties. 31) Subsequently, this led to the discovery of the three-dimensional crystal structures of rat and human FcRn alone and rat FcRn in complex with the rat IgG Fc. [32] [33] [34] The extracellular part of the FcRn heavy chain is divided into three separate subdomains denoted as a1, a2 and a3. The amino terminal a1-a2 domains form eight antiparallel b-pleated sheets topped by two long a-helices connected to the a3-domain. The non-covalently associated b2-microglobulin chain interacts with the heavy chain via residues located under the a1-a2 platform in addition to the a3-domain. The overall tertiary structure is quite similar to MHC class I except that the counterpart of the MHC peptide binding groove is occluded in FcRn. Thus, FcRn does not bind to antigenic peptides. The crystal structure of human FcRn is given in Figure 2A .
pH Dependent bi-Functional Binding
A hallmark finding regarding interactions of IgG and albumin with FcRn is that they both bind in a strictly pH dependent fashion, binding at acidic pH and release or no binding at physiological or neutral pH. 10, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] This is due to the presence of conserved histidine residues. The imidazole group of histidine is protonated at acidic pH and nonprotonated or neutral at physiological pH. The IgG-FcRn interaction is dependent on the two conserved H310 and H435 within the IgG Fc CH2-CH3 domain interface. 10, 35, 36, 43, 44) Hydrophobic I253 is involved. These histidine residues interact with acidic residues within the FcRn heavy chain. 33) An illustration of the interaction based on the co-crystal of rat FcRn and rat IgG Fc is shown in Figure 2B . The FcRn-albumin interaction is less well studied but we have shown that mutation of the conserved His166 to alanine in the human FcRn a2-domain (highlighted in Fig. 2A ) is crucial for binding to HSA, while IgG binding was not affected. 43) Furthermore, the binding site on albumin has been demonstrated to be localized to the carboxy terminal domain III 44) although the critical residues involved have not been defined. Importantly, both IgG and albumin interact simultaneously with FcRn in a pH dependent fashion at distal binding sites. 45, 46) 
FcRn Functions
The pH dependence of both FcRn-ligand interactions is fundamental for all FcRn functions described. This is evident from its important role in the homeostatic regulation of the levels of IgG and albumin in the circulation. Generally, FcRn is considered to reside predominantly within acidified intracellular compartments of cells that have large contact area with the blood circulation such as the vascular endothelium. Circulating IgG and albumin continuously taken up by fluid phase endocytosis subsequently bind to the receptor as a result of the pH gradient formed in the endocytic pathway by ATPases that triggers protonation of the histidine residues. 47, 48) The ternary IgG-FcRn-albumin complex then returns to the cell surface membrane, where exposure to physiological pH of the bloodstream triggers release of ligands back into the circulation in prolonged release or kiss-andrun exocytotic events. 49, 50) Thus, pH dependence is a prerequisite for the salvage of IgG and albumin from intracellular lysosomal degradation. Although FcRn is expressed at multiple sites throughout the body, the cell types that participate in FcRn mediated IgG and albumin homeostasis have only recently been well defined. The primary site for FcRn mediated recycling is presumed to be endothelial cells covering the bloodstream, and Ward and coworkers very recently proved this in mice conditionally deleted for endothelial FcRn expression. 51) A large body of evidence indicates that FcRn expressed by hematopoietic cells such as dendritic cells plays a key role in half-life regulation. 26, 51, 52) In contrast to monomeric IgG, IgG-containing immune complexes are eliminated rapidly from the circulation. 52) Thus, FcRn does not rescue immune complexes, a finding that makes sense as IgG bound foreign pathogenic antigens is to be removed from the body. A reasonable explanation is that FcRn collaborates with other Fcg receptors in immune surveillance. This is in line with recent reports on the dependence of FcRn in antigen sampling and presentation on dendritic cells and phagocytosis in neutrophils. 47, 52) The impact of FcRn in half-life regulation of IgG and albumin is astonishing and is shown by the fact that the albumin level is 60% lower in FcRn deficient mice than in wild type mice, while the serum level is 70-80% lower for IgG. 10, 53) Transport of IgG and immune complexes over epithelial barriers, such as in the rodent intestinal epithelial, is dependent on the presence of the Fc part of IgG. 54) In contrast to developmental downregulation of FcRn in the rodent intestinal epithelium, the human form of FcRn is expressed at mucosal surfaces throughout life. 48, 55) In a human FcRn transgenic mouse model where FcRn is constitutively expressed in the gut, IgG-immune complexes where transcytosed across the epithelium for entry into the lamina propria and activation of dendritic cells. 54, 56) Thus possibly, FcRn, in addition to the polymeric Ig receptor for IgA, orchestrates antibody mediated response at mucosal barriers. Notably, FcRn is also expressed in lung tissues and it has been demonstrated that alveolar epithelial cells transcytose IgG. 57, 58) In parallel with FcRn mediated transport via the yolk sac in rabbits and mice reported by Brambell and others, 12, 13, 59, 60) the human form of FcRn is expressed in syncytiotrophoblasts of the placenta. 28, 29) Here it is the main antenatal transporter of maternal IgG to the fetus during the third trimester Thus, FcRn has evolved to be fundamentally important to the transfer of passive immunity to the fetus that also secures protection during the first weeks of life.
The kidneys are important for the filtration of plasma and carry out selective secretion as a function of molecular weight, as proteins above approximately 60 kDa are retained. This means that albumin (66.7 kDa) and IgG (150-170 kDa) are prevented from glomerular secretion into the urine. A topic of controversy has been why the glomerular basement membrane does not clog up with large amounts of serum proteins. FcRn is expressed in kidney cells, 22, 23) and was recently shown to play an active role in the removal of IgG from the glomerular basement membrane, since IgG accumulates at this site in mice lacking FcRn. 24) This may shed new light on the pathophysiology of nephrotoxicity.
The liver is a vital organ responsible for the albumin synthesis necessary to reach the remarkable serum albumin concentration of 40-45 mg/ml. In addition to the rate of synthesis, FcRn recycling is fundamentally important for albumin homeostasis. The capacity of FcRn to recycle albumin is such that the amount of albumin saved from degradation is the same as that produced by the liver. 61) Interestingly, FcRn is expressed in several different liver cell types such as rodent hepatocytes and hepatic sinusoidal cells, in addition to strong expression in Kupffer cells. [25] [26] [27] Furthermore, FcRn is expressed in human hepatocytic cell lines and tissue (M. B. Daba, J. T. Andersen, I Sandlie, unpublished data). Despite these histological findings, the functional role of FcRn in different liver cells is poorly understood. Studies in rats suggest that FcRn situated in hepatocytes mediates transcellular serum to bile transport of IgG in addition to IgG protection from degradation. 25) Serum to bile transport of IgG has been shown unaffected in mice functionally deleted for FcRn. 27) Nevertheless, one role for FcRn in IgG mediated liver transport/recycling is strongly indicated in tumor studies where scFv-Fc fragments with attenuated FcRn binding properties accumulate in the liver, while variants with intact FcRn binding do not. 62) Hypoalbuminemia induces increased liver synthesis of albumin and other liver produced proteins. 1, 63) This is also the case in FcRn deficient mice. 61, 64) Since human FcRn does not bind to mouse IgG, 65, 66) the half-life of endogenous IgG is very low in mice knock out for endogenous FcRn and transgenic for human FcRn. 53, 67) Interestingly, these mice rescue mouse albumin from degradation in the absence of IgG binding to human FcRn. 10) This correlates with pH dependent binding of mouse albumin to recombinant soluble human FcRn (J. T. Andersen and I. Sandlie, unpublished). Analbuminemia is a rare recessive disorder in which subjects have low or no circulating albumin. 1) This condition is caused by a variety of mutations in the albumin gene and is exhibited only by subjects homozygous for the defect. A variety of albumin allelic gene variants has been reported, 68) and several of which generate carboxy terminal truncated products partially or completely lacking the DIII crucial for FcRn binding. 69) This fact would most likely explain their low serum persistence.
It is also notable that IgA can be found in blood covalently bound to albumin. 70, 71) While the concentration in blood is normally very low, the amount is dramatically increased (¿2 mg/ml) in IgA myeloma patients. 72) Crystallographic characterization has revealed that albumin is covalently linked via C34 to C471 which is found in the secretory tailpiece of IgA. 70) This suggests that albumin bound IgA is recycled via the FcRn pathway and thus achieves increased serum persistence.
Another interesting discovery is that FcRn is highly expressed in the endothelium and choroid plexus of the central nervous system (CNS).
73)
Although this system is a site of immune privilege, the blood brain barrier transiently allows passage as a response to cytokines released during inflammation, as reviewed elsewhere. 74) Subsequently, IgG and albumin enter the CNS and previous data show that transport of IgG is dependent on the Fc part whereas Fab fragments does not interfere with transport efficiency. 75) Furthermore, data strongly suggest that FcRn is the involved receptor 76) since systemic and cerebral injections of amyloid plaque specific IgGs in an Alzheimer disease mouse model cause plaque proteins to enter the systemic circulation in wild type mice but not in FcRn deficient mice.
76)
Therapeutic and Diagnostic Utilities
The diverse functions of FcRn may be utilized for therapeutic and diagnostic purposes. The most obvious reason is its role as a regulator of IgG and albumin half-life. Bioactive peptides and small proteins obtained from combinatorial libraries or molecular engineering are candidates for therapeutic or diagnostic use. However, due to very short half-lives, from minutes to hours, they fail to show convincing effects in vivo.
77,78)
The main reason is their size below the renal clearance threshold as well as their susceptibility to degradation by proteases, obstacles that limit the transition from lead to drug on the market. By taking advantage of the prolonged half-life of IgG or albumin controlled by FcRn, their efficiency may be overcome and translated into clinical use.
IgG Fusion and Engineering
The development of hybridoma technology is a breakthrough that has allowed manufacturing of rodent mAbs in large amounts. 79) Molecular engineering allows design of mAbs with desired binding specificity and effector functions. Today, nearly 30 monoclonal Abs (mAbs) have been approved by the US Food and Drug Administration (FDA) for treatment of different diseases, while hundreds of promising candidates are evaluated in clinical trials. 8-0-82) IgG is the only Ab isotype with an extended half-life, and thus it is no coincidence that all approved Abs are built on IgG.
The first generation of mAbs was of murine origin. 79, 83) After entering the clinic, their in vivo efficiency was tremendously disappointing as they were rapidly cleared from the circulation, a phenomenon that at the time was explained to result from human anti-mouse Ab (HAMA) response. Consequently, their therapeutic efficiency was improved by reducing their immunogenicity by genetic engineering. Murine sequences were partially or completely replaced with human counterparts (humanization), 84, 85) a strategy that reduce the HAMA-effect and dramatically increase the half-life to that of endogenous IgG. The main reason for the reduced half-life can now be attributed to the strictly selective binding properties of the human form of FcRn that discriminates against binding to murine IgGs. 65, 86) A molecular explanation has been given by Ward and coworkers who demonstrated that residues extending away from the core interaction site are responsible. 86) To extend the half-life of small proteins, such as cytokines, genetic fusion to the Fc part of IgG1 has been broadly used as reviewed elsewhere. 87, 88) Extending halflife by fusion to IgG Fc increases bioavailability and allows less frequent administration and may therefore also have great impact on the cost of treatment. For instance, a phage display selected thrombopoietin agonistic peptide fused to the Fc part of human IgG1 (Nplate TM , romiplostim) is an FDA approved molecule for the treatment of thrombocytopenia. 89) Another successful drug is Fc fusion to the tumor necrosis factor (TNF) receptor (Etanercept, Enbrel TM ) that prevents binding of TNF-a to cell-surface TNF receptors and thus inhibits pro-inflammatory activity in rheumatoid arthritis patients. 90) Elegant studies have taken advantage of FcRn expressed in upper and central airways of the lung, in that Fc-fused erythropoietin reaches the systemic circulation and subsequently increases erythrocyte production after such pulmonary delivery. 57, 58) In addition to genetically fused Fc therapeutics, significant progress over the past years has lead to engineering of the Fc part so as to alter its pharmacokinetics via modulation of FcRn interaction. [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] To design such IgG molecules, single amino acid mutations are introduced. The main challenge when aiming for improved half-life is that the binding affinity should only be increased at acidic pH and not at neutral pH. For instance, a humanized anti-respiratory syncytial virus IgG1 mutant with improved affinity at pH 6.0 but not at pH 7.4, showed 4-fold improvement in serum half-life in cynomolgus monkeys. 98) Human IgG1 Fc mutants with increased affinity at both pH 6.0 and pH 7.4 showed decreased halflife in mice. 97) Engineered Abs that bind strongly to FcRn, but with reduced pH dependence may however be attractive as modulators of endogenous IgG levels, since they stay bound to the receptor and thus act as FcRn blockers. 91, 93) Such FcRn blockers, abrogated as Abdegs (Abs that enhance IgG degradation) have been shown to induce transient and rapid elimination of IgG in model systems. 91) Abdegs may find their use in treatment of autoimmunity where pathogenic IgG dominates, or they can be used to modulate the half-life of IgG-based immunoconjugates or toxins.
The half-life of endogenous IgG depends on its concentration in the circulation since FcRn recycling is a saturable process. In some cases of autoimmunity, it may be advantageous to modulate the levels of endogenous IgG, as high amounts of pathogenic IgGs are present in blood. Accelerating IgG clearance can be induced by administration of high doses of exogenous IgG, so-called intravenous immunoglobulin (IVIG) therapy. 101, 102) This saturates the FcRn pathway and consequently, pathogenic IgGs are destined for degradation. This strategy has been demonstrated efficient in several autoimmune mouse model systems 103, 104) and improves Ab-based tumor imaging in humans. 105) Although FcRn saturation using IVIG therapy forces clearance of endogenous IgG, this anti-inflammatory effect is also mediated by the presence of sialylated IgG in IVIG preparations, that presumably triggers up-regulation of the inhibitory Fcg receptor IIB. 106, 107) A more direct way is to specifically interfere with pH dependent ligand binding using anti FcRn mAbs to block IgG binding and subsequently enhance IgG clearance in vivo. 108, 109) Furthermore, a chemically optimized phage display selected peptide, SYN1436, with high specificity for FcRn, shows dose-dependent reduction of endogenous IgG by up to remarkable 80% in cynomolgus monkeys. 110) Alternatively, peptides targeting the IgG Fc part have also been selected, but whether they interfere with FcRn binding, remains to be shown. 111, 112) Engineered mAbs with reduced half-life may well be used as diagnostics rather than therapeutics. A range of different half-lives is obtained by mutating single residues in the constant Fc elbow region that affect FcRn binding (I253, H310, H435) . 36, 59) This has been shown a favorable strategy to fine-tune the pharmacokinetics of IgG based immunoconjugates used for tumor targeting and imaging applications. 62, 113, 114) Such half-life tailoring is broadly applicable to all IgG mAbs and Fc fusions to control their pharmacokinetic properties.
Albumin Fusion and Engineering
The long half-life of albumin was well recognized before its relationship with FcRn was discovered, and utilized to enhance the in vivo pharmacokinetics of therapeutic substances by covalently coupling to albumin. Tumors and inflamed tissues show increased accumulation of albumin as a result of leaky capillaries and defective lymphatic drainage and this increases the fluid phase uptake that favors engulfment of abundant albumin used as a natural nitrogen and energy source. 1, 115) Consequently, albumin conjugated chemical therapeutics accumulate at the site of tumor or inflammation. This phenomenon has been extensively used for the antimetabolite substance methotrexate (albumin-MTX) in treatment of renal carcinomas and rheumatoid arthritis. [116] [117] [118] The ability of albumin to bind to fatty acids has also been therapeutically explored by chemical coupling of small proteins to such``albumin affinity tags''. [119] [120] [121] The affinity for albumin determines the duration of the therapeutic effect. An example is the insulin analogue detemir (Levemir, Novo Nordisk) approved for treatment of diabetes 1 and 2 mellitus. It is engineered to include a C14 fatty acid that binds to endogenous albumin when administrated post subcutaneously, and thus prolongs its bioavailability. 122) Another sophisticated way to target albumin is to take advantage of a unique and exposed cysteine residue (C34) in DI of albumin, highlighted in Figure 1A . The technology is named Drug Affinity Complex (DAC TM ) and consists of three elements: a drug, a connector and a reactive chemical group such as a maleimide group that allows rapid, specific and permanent binding of the drug to albumin. The strategy can be utilized to conjugate drugs to both exogenous and endogenous albumin. Clinically, albumin malemide conjugated exendin-4, a glucagon-like peptide-1 homolog (CJC-1131) for treatment of type 2 diabetes, has entered clinical trials with promising results. 123) While glucagon-like peptide-1 analogues show very short half-lives in hours, albumin C34 targeting greatly improves the half-life to 9-15 days in humans. 123) Such targeting would not affect FcRn recycling since C34 is located within DI, distally from the receptor binding site within DIII.
The development of albumin-based nanoparticle technology, in which a lipophilic drug is encapsulated with albumin under high pressure, has been extensively investigated. 124) This has led to the FDA approval of albumin encapsulated mitotic inhibitor paclitaxel (Abraxane TM ) for treatment of metastatic breast cancer, which failed to improve by combination therapy. 125, 126) Notably, no reports have so far addressed the impact of such albumin based drugs on FcRn binding and transport.
Several reports explore the idea of genetic fusion of therapeutic proteins to albumin, as for instance CD4, 127) hirudin, 128) insulin (Albulin), 129) granulocyte colony stimulating factor (Albugranin), 130) growth hormone (Albutropin) 131) and interferon a and b (Albuferon). [132] [133] [134] In all cases, the fusions showed improved pharmacokinetics compared to non-fused counterparts. Furthermore, in contrast to in vitro chemical conjugation, direct genetic fusion is favorable in terms of no need for cross-linking.
Clinically, the leading candidate is albumin fused interferon a2a. 133) In contrast to recombinant interferon a2a with a short half-life of only about 4 hours in humans, albumin fusion increases the half-life to 141 hours. 132, 133) This is more than can be achieved by conjugation to PEG, which increases the half-life to 40 hours. 135) Coupling of small Ab fragments to long-lived albumin has also been demonstrated a good strategy to improve the bioavailability of this important class of molecules. This was first shown for chemical cross-linking of Fab to rat albumin that increased the half-life to that observed for non-conjugated rat albumin. 136) Similarly, a scFv fragment genetically fused to HSA showed the same half-life as HSA in rats, although below that of rat albumin. 136) Genetic fusion of Ab fragments has been extended to bispecific single chain diabodies (scDb) that target both carcinoembryonic antigen (CEA) and the T cell receptor complex molecule CD3. 137) Such scDb has been reported to direct T lymphocytes to tumors for inducement of cell destruction. 138) To scDb genetically fused to HSA was shown to bind both cell targets and although T cell activation was reduced to some extent, the fusion showed improved half-life in mice compared with naked scDb. 137) In addition, albumin fusion to an anti-CEA scFv (``immunobulin'') has been explored as a tumor imaging reagent in a colorectal carcinoma xenografted mouse model that yielded improved half-life and enhanced tumor targeting potential compared with non-fused anti-CEA scFv. 139) Thus, genetic fusion of small Ab fragments to albumin provides Ab fragments with the beneficial pharmacokinetic properties of albumin.
Half-life Modification by Albumin Targeting
An equally attractive approach is to target endogenous albumin in a reversible non-covalent manner. Such an approach has been demonstrated using a bispecific F(ab?)2 fragment designed to target both rat albumin and TNF. 136) The anti-albumin Fab arm bound strongly to endogenous albumin and the bispecific F(ab?)2 showed improved half-life in rats compared to a non-albumin binding F(ab?)2. If the anti-albumin Fab is not directed towards DIII of albumin, such a complex may indeed be rescued via the FcRn pathway.
Human domain antibodies (dAbs) with specificity for albumin have been selected with phage display technology (AlbudAbs). 140) Their half-lives in rats were 43-53 hours, very similar to the half-life of endogenous rat albumin, which is 53 hours.
Albumin has also been targeted with peptides conferring albumin specificity. Such peptides have been isolated using phage display technology 141) and genetic fusion of an anti tissue factor Fab fragment derived from the FDA approved trastuzumab (Herceptin TM ), bound simultaneously to albumin and the antigen. This resulted in 26 and 37 fold improved half-life in mice and rabbits, respectively, compared with non-fused Fab. 141) The affinity of such selected anti-albumin peptides is crucial for improvement of half-life, as Fab fragments fused to peptides with a variety of affinities generated a spectrum of half-life profiles where a molecule fused to a peptide with low affinity was eliminated more rapidly than those with fused high affinity peptides. 142) A comparison of trastuzumab and the corresponding Fab-peptide fusion in HER2 xenografted mice clearly showed small peptide fusion to rapidly target the tumor site, although it was eliminated from the circulation faster than trastuzumab. 143) Tissue distribution was also affected as the peptide fusion molecule showed less kidney accumulation compared with non-fused Fab. Strikingly, this was also the case for Fab genetically fused to a small albumin binding domain (ABD) from the Streptococcus strain G148 protein G. 144) ABD has been applied to other therapeutic proteins as well to extend half-life. Early reports documented extended half-life of ABD-fused soluble complement receptor 1 (sCR1) and soluble CD4 in rodents compared with non-fused constructs. 145, 146) More recently, ABD has been genetically fused to a divalent anti-HER2 Affibody (ZHER2:342)2 molecule.
147)
An Affibody molecule is a small domain (¿7 kDa) derived from the IgG binding domain of staphylococcal protein A used as a scaffold for construction of combinatorial libraries and target selections. 148) Radiolabeled ABD-(ZHER2:342)2 evaluated in HER2 positive microxenograft mice gave rise to high tumor to normal tissue ratios, and renal accumulation was reduced by 25 fold compared to non-fused (ZHER2:342)2. 147) ABD fused to a bispecific scDb (scDbCEACD3-ABD) designed to target cytotoxic T cells via CD3 to CEA positive tumor showed 5-6 fold increased half-life and retained activity although reduced compared with scDbCEACD3. 149) A spectrum of ABD variants with different affinities for albumin has been engineered and these variants may be used to fine tune the biodistribution of ABD fused therapeutics or diagnostics. 150) Taken together, fusion of short anti-albumin peptides, ABD or AlbudAbs to therapeutic proteins may be used to tailor half-life as a function of albumin affinity in a manner that has impact on biodistribution and organ deposition.
Future Perspectives
In relation to FcRn, several questions remain to be answered, as none of the studies reviewed on albumin fusion and targeting has actually directly addressed the im-pact of FcRn. If albumin targeting does not affect the pH dependent interaction between FcRn and albumin, it is likely that FcRn indeed recycles and rescues such albumin fused or targeted molecules. A prerequisite is that they bind to albumin with adequate affinity at both neutral as well as acidic pH in a manner similar to that already described for the IgG-FcRn interaction. Recent reports on albumin mutants with altered stability, halflife and organ deposition are highly interesting. [151] [152] [153] [154] Whether reported albumin modifications affect FcRn binding is not known.
A molecular understanding of interactions of IgG and albumin with FcRn will have impact on development of novel engineered IgG and albumin variants optimized for therapeutic or diagnostic use. The long serum half-life of IgG has greatly contributed to the clinical success of this class of therapeutics. Strategies utilizing the long half-life of IgG and albumin may be more generally translated into re-engineering of different classes of protein scaffolds currently evaluated in preclinical and clinical trials as a link to improve their pharmacokinetics, as for instance Affibodies, 155) designed ankyrin repeat proteins (DARPins) 156) and Nanobodies. 157) In the context of re-engineering of such molecules, it will be valuable to investigate whether amino or carboxy terminal fusions affect target binding properties and pH dependent binding to FcRn.
The choice of appropriate preclinical model systems is highly relevant to determine pharmacokinetic parameters of therapeutically engineered IgGs, Fc and albumin fusions. Although primates are likely the best systems for such evaluations, rodents are used for screening. However, the results obtained should be carefully analyzed, as differences in biology across species will clearly affect the results. This important topic has been pinpointed for human FcRn that does not bind to mouse IgGs. 65, 86) In line with this, endogenous mouse IgG is not recycled and rescued from degradation in mice knock out for mouse FcRn and transgenic for human FcRn. 10, 53) This mouse model is probably still the best for evaluation of human FcRn binding therapeutics and diagnostics. Crossspecies FcRn interaction with albumin may also have great impact. For instance, the half-life of HSA is reported to be only 15 hours in rats compared with 49 hours for rat albumin. 136) Finally, extrapolation to a human setting needs to take into account that the half-life of endogenous albumin in rodents is only about 1.5-2.5 days, compared to 19 days in humans. 1, 10, 158) 
Concluding Remarks
The current molecular understanding of the pH dependent binding of IgG and albumin to separate binding sites on FcRn has given a molecular explanation on how the receptor binds and transports its cargo within and through different cell layers of the body. This pH dependence has evolved to secure the versatile roles of FcRn in physiological and immunological processes. Especially, the fundamental role of FcRn in the homeostatic regulation of IgG and albumin has inspired the development of novel engineered IgG variants, IgG Fc and albumin fusion molecules as well as molecules that target albumin, all with altered therapeutic and diagnostic properties. Moreover, the role of FcRn in selective transport across mucosal barriers and placenta as well as its recently described contribution to antigen presentation by immune cells will certainly lead to further research to unmask the molecular and cellular secrets of FcRn.
